Key Highlights

● Second-quarter Revenue fell 5.5% to $587.3 million with a $221.7 million non-cash Goodwill Impairment recorded.

● Adjusted EBITDA was $247.2 million, a 42.1% margin, compared with $261.6 million a year earlier.

● Management reaffirmed its full-year 2026 guidance, including adjusted EBITDA of $980 million to $1.04 billion.

Clarivate (NYSE:CLVT), the information-services and analytics group behind well-known research and intellectual-property platforms, is drawing investor attention as it reshapes its portfolio. The company recently reported second-quarter 2026 results that combined a large non-cash goodwill impairment with a reaffirmed full-year outlook.

Latest Company Context

Clarivate released second-quarter results on July 29, 2026. Revenue was $587.3 million, down 5.5% from $621.4 million a year earlier, with organic revenue down 1.5%. The company recorded a net loss of $268.6 million, or $0.42 per diluted share, which included a $221.7 million non-cash goodwill impairment. Adjusted Net Income was $123.1 million, or $0.19 per diluted share, compared with $0.18 a year earlier. Adjusted EBITDA was $247.2 million, a Margin of 42.1%, against $261.6 million previously. Operating Cash Flow was $98.7 million and free cash flow was $44.0 million. The revenue mix showed subscription revenue of $403.3 million, re-occurring revenue of $109.3 million and transactional revenue of $74.7 million, the last of which fell 30.1%. At June 30 the company held $217.7 million of cash and $4.25 billion of total debt.

Key Business and index Drivers

Management reaffirmed its 2026 outlook, which excludes further acquisitions or divestitures. Guidance calls for organic annual contract value growth of 2.0% to 3.0%, adjusted EBITDA of $980 million to $1.04 billion, adjusted diluted EPS of $0.70 to $0.80 and free cash flow of $365 million to $435 million. Revenue guidance is presented both including discontinued operations, at $2.30 billion to $2.42 billion, and excluding them, at $1.94 billion to $2.04 billion. The distinction matters because the Life Sciences and Healthcare segment is set to move into discontinued-operations reporting beginning in the third quarter of 2026, signalling a more focused company.

Key drivers include subscription renewal rates, the decline in transactional revenue, and how effectively cash flow can be directed toward a Debt load that remains large relative to cash. One summary described the quarter as a fifth straight earnings-per-share beat alongside a revenue miss, which is an analyst-style characterisation rather than company guidance.

What Investors Should Watch

Investors may watch the third-quarter report for the first presentation of Life Sciences and Healthcare as discontinued operations, since that could change how headline revenue and margins compare with prior periods. They may also track organic annual contract value growth against the 2.0% to 3.0% target, as it is a leading indicator for recurring revenue. Debt reduction is another area of focus: with total debt above $4.2 billion, interest costs and any proceeds from divestitures could materially affect earnings. Free cash flow conversion, which was $44.0 million in the quarter, may indicate whether the full-year range is achievable.

Impairment, Debt and a Reshaped Reporting Perimeter

Clarivate presents a mixed picture: steady adjusted profitability and reaffirmed guidance on one side, and shrinking reported revenue, a sizeable impairment and heavy debt on the other. The coming quarter, with its restructured reporting, may provide a clearer view of the continuing business.